Literature DB >> 32278720

Anticancer effect of X-Ray triggered methotrexate conjugated albumin coated bismuth sulfide nanoparticles on SW480 colon cancer cell line.

Mohammad Hasan Faghfoori1, Hamed Nosrati2, Hamed Rezaeejam3, Jalil Charmi4, Saeed Kaboli1, Behrooz Johari5, Hossein Danafar6.   

Abstract

The application of nanoparticles (NPs) as radio-sensitizers and carriers has opened up a new horizon to overcome the limitations of chemo and radiotherapy. In this study, bovine serum albumin-coated Bi2S3 NPs (Bi2S3@BSA NPs) were synthesized and evaluated in terms of their ability to be used as a radio-sensitizer and carrier for methotrexate (MTX). Physicochemical properties of MTX conjugated Bi2S3@BSA NPs (Bi2S3@BSA-MTX NPs) were characterized by DLS, TEM, FTIR, UV/Vis, and XRD analyses. After the evaluation of cellular uptake and intracellular localization, the cytotoxicity of the combination of Bi2S3@BSA-MTX NPs and X-Ray radiation was analyzed against the SW480 cell line. The synthesized NPs exhibited spherical-like shapes and homogenous morphology, possessing a hydrodynamic diameter of 140.2 ± 5.71 nm (mean ± SD) and zeta potential of -25 mV. Also, the release study showed that the release of MTX is faster and higher in the presence of the proteinase K enzyme than the absence of the enzyme. The results of in-vitro chemo-radiation therapy indicated that the viability of treated cells with Bi2S3@BSA-MTX NPs is significantly lower than the cells treated with Bi2S3@BSA NPs. Furthermore, cells treated with Bi2S3@BSA-MTX NPs showed a lower degree of viability when combined with X-Ray radiation in comparison with the absence of irradiation, which confirmed the ability of the Bi2S3@BSA-MTX NPs as radio-sensitizer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bismuth sulfide; Bovine serum albumin; Colorectal cancer; Methotrexate; X-ray irradiation

Mesh:

Substances:

Year:  2020        PMID: 32278720     DOI: 10.1016/j.ijpharm.2020.119320

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer.

Authors:  Pedro Cruz-Nova; Alejandra Ancira-Cortez; Guillermina Ferro-Flores; Blanca Ocampo-García; Brenda Gibbens-Bandala
Journal:  Pharmaceutics       Date:  2022-05-20       Impact factor: 6.525

2.  Hybrid of niosomes and bio-synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment.

Authors:  Mahmoud Gharbavi; Behrooz Johari; Navid Mousazadeh; Bahareh Rahimi; Milad Parvinzad Leilan; Seyed Sadegh Eslami; Ali Sharafi
Journal:  Mol Biol Rep       Date:  2020-08-07       Impact factor: 2.316

3.  Methotrexate and Cetuximab-Biological Impact on Non-Tumorigenic Models: In Vitro and In Ovo Assessments.

Authors:  Andreea M Kis; Ioana Macasoi; Corina Paul; Matilda Radulescu; Roxana Buzatu; Claudia G Watz; Adelina Cheveresan; Delia Berceanu; Iulia Pinzaru; Stefania Dinu; Aniko Manea; Marioara Poenaru; Claudia Borza; Cristina A Dehelean
Journal:  Medicina (Kaunas)       Date:  2022-01-22       Impact factor: 2.430

4.  Gold Nanoparticle-Incorporated Chitosan Nanogels as a Theranostic Nanoplatform for CT Imaging and Tumour Chemotherapy.

Authors:  Zhe Liu; Dong Zhou; Xuan Yan; Lan Xiao; Pei Wang; Junchao Wei; Lan Liao
Journal:  Int J Nanomedicine       Date:  2022-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.